820
Participants
Start Date
March 31, 2013
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2016
second- or third-line glucose-lowering diabetes treatment
Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
University of Exeter, Exeter
Oxford University Hospitals NHS Trust, Oxford
University of Newcastle, Newcastle upon Tyne
University of Glasgow, Glasgow
King's College University of London, London
University of Exeter
OTHER
King's College London
OTHER
King's College Hospital NHS Trust
OTHER
University of Glasgow
OTHER
NHS Greater Glasgow and Clyde
OTHER
Newcastle University
OTHER
Newcastle-upon-Tyne Hospitals NHS Trust
OTHER
Oxford University Hospitals NHS Trust
OTHER
Royal Devon and Exeter NHS Foundation Trust
OTHER